Author

Kristin Ryan

OpenAlex ID: A5122834406

Efficacy and safety of lirafugratinib in FGFRi -naïve cholangiocarcinoma (CCA) patients harboring FGFR2 fusions/rearrangements ( FGFR2 f/r).

2026 · Antoine Hollebecque, Mitesh J. Borad, et al. · Journal of Clinical Oncology · 6

A phase 2, open-label, single-arm study of lirafugratinib in patients with previously treated, unresectable, locally advanced, or metastatic solid tumors (excluding cholangiocarcinoma) with FGFR2 fusion or rearrangement.

2026 · Richard D. Kim, Antoine Hollebecque, et al. · Journal of Clinical Oncology

Abstract 294: Comparative biochemical kinase activity analysis identifies lirafugratinib as a highly selective FGFR2 inhibitor.

2026 · Alison M. Schram, Grace Lee, et al. · Cancer Research

Works count: 3

Citation count: 6

H-index: 1

I10-index: